Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	43.65B +65.2%
Revenue (ttm)	4.76B +48.5%
Net Income	1.98B +52.9%
EPS	4.41 +53.1%
Shares Out	450.00M
PE Ratio	21.99
Forward PE	21.88
Dividend	0.80 (0.82%)
Ex-Dividend Date	Sep 10, 2025

Volume	2,375,420
Average Volume	3,951,557
Open	98.24
Previous Close	98.07
Day's Range	96.96 - 98.97
52-Week Range	67.60 - 122.20
Beta	0.39
RSI	40.98
Earnings Date	Apr 23, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,823
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2024, SHA:688578's revenue was 3.56 billion, an increase of 76.29% compared to the previous year's 2.02 billion. Earnings were 1.43 billion, an increase of 121.97%.